



24 February 2025

To: NZ RegCo
11 Cable Street
Wellington
New Zealand

issuer@nzregco.com

Request for trading halt: Ryman Healthcare Limited (NZX Codes: RYM and RYM010)

We request a trading halt to be applied to Ryman Healthcare Limited's (**Ryman**) ordinary shares (ISIN: NZRYME0001S4) and fixed rate, secured, unsubordinated bonds (ISIN: NZRYMD0010L2) under NZX Listing Rule 9.9.1(a) and set out below details of the request as per the rules of NZX.

We would like the trading halt to commence from prior to the commencement of trading today, 24 February 2025 and being lifted at the earlier of: (i) announcement of completion of the placement and institutional offer described below; and (ii) opening of trading on the NZX on 26 February 2025.

Reasons for trading halt:

Ryman is proposing to raise approximately NZ\$1 billion of new capital by way of an approximately NZ\$313 million placement (**Placement**) to be conducted by Jarden Securities Limited, Craigs Investment Partners Limited (**Craigs**) and Forsyth Barr Limited (together, **Joint Lead Managers**), together with an approximately NZ\$688 million accelerated non-renounceable entitlement offer (**ANREO**). The Placement and the ANREO are to be fully underwritten by Jarden Partners Limited (together with Jarden Securities Limited, **Jarden**), Craigs and Forsyth Barr Group Limited (together with Forsyth Barr Limited, **Forsyth Barr**).

Ryman considers that a trading halt is desirable to enable Jarden, Craigs, Forsyth Barr and Ryman to conduct the Placement and the institutional entitlement offer component of the ANREO and determine the allocation of shares. Ryman considers that, but for the trading halt, the Placement and the institutional entitlement offer component of the ANREO process would impact a fair, orderly or transparent market as information about the Placement, the institutional offer component of the ANREO or take up by investors may be known by some market participants and not others, so the market would not be trading on a fully informed basis.

As soon as the Placement and institutional entitlement offer component of the ANREO and the allocation of shares under them is completed, Ryman will be in a position to release details of the results of the Placement and institutional entitlement offer component of the ANREO to the market. Ryman believes that such information will be price sensitive.

How long we want the trading halt to last:

We would like the trading halt to last up to two trading days, commencing from the commencement of trading on 24 February 2025 and being lifted at the earlier of: (i) announcement of the outcome of the Placement and institutional entitlement offer component of the ANREO, and (ii) opening of trading on the NZX on 26 February 2025.

Ryman Healthcare Limited
03 366 4069 | 0800 588 222
92 Russley Road, Christchurch
PO Box 771, Christchurch 8140
rymanhealthcare.co.nz

The event we expect to happen that will end the trading halt:

We expect the trading halt to end once we are in a position to announce the outcome of the Placement and institutional entitlement offer component of the ANREO. We expect this to occur on 25 February 2025 or before market open on the NZX on 26 February 2025.

Other information necessary to inform the market about the trading halt or that NZ RegCo has requested:

We do not believe that there is any other information necessary to inform the market about the trading halt.

We confirm that we are not aware of any reason why the trading halt should not be granted.

Yours sincerely

A handwritten signature in blue ink, appearing to read 'Morgan Powell', is positioned above the printed name and title.

Morgan Powell
General Counsel